Novartis Investigative Site

Samsun 55200

1 studies enrolling now · 14 studies all time

What they study most

Carcinoma, Renal Cell, Cardiovascular Disease and Lipoprotein(a), Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Chronic Spontaneous Urticaria, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Early Breast Cancer, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Thrombocytopaenia

Studies at this site

• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. — Completed
• Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs — Completed
• A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines — Completed
• Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab — Stopped early
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) — Completed
• A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma — Completed
• Safety and Efficacy of BKM120 in Relapsed and Refractory NHL — Completed
• A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) — Stopped early
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia — NO_LONGER_AVAILABLE